Sera PrognosticsSERA -0.82%70 Quick Ratio is 2.12 as of Mar. 2026, which is 40% below its 10-year median of 3.51. GuruFocus rates SERA with a GF Score™ of 70/100 and a GF Value™ of $1.86 (Fairly Valued). The stock has 5 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Sera Prognostics ranks better than 55.5% on this metric.
Sera Prognostics has a quick ratio of 2.12. It generally indicates good short-term financial strength.
The historical rank and industry rank for Sera Prognostics's Quick Ratio or its related term are showing as below:
SERA'
s Quick Ratio Range Over the Past 10 Years
Min: 1.22 Med: 3.51 Max: 34.53
Current: 2.12
During the past 7 years, Sera Prognostics's highest Quick Ratio was 34.53. The lowest was 1.22. And the median was 3.51.
SERA's Quick Ratio is ranked better than 55.5% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 1.865
vs SERA: 2.12
Sera Prognostics (NAS:SERA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Sera Prognostics Quick Ratio Related Terms
Sera Prognostics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Sera Prognostics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sera Prognostics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sera Prognostics Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Sera Prognostics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Sera Prognostics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sera Prognostics (SERA) has a Quick Ratio of 2.12 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Sera Prognostics and its competitors. This is 40% below median its historical median of 3.51. Over the past decade, Sera Prognostics' Quick Ratio has ranged from 1.22 to 34.53. According to the industry distribution chart, Sera Prognostics ranks #380 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 44.5%.
Is Sera Prognostics' Quick Ratio too high?
Sera Prognostics' current Quick Ratio of 2.12 is 40% below median its 10-year median of 3.51. Over the past 10 years, this metric has ranged from a low of 1.22 to a high of 34.53. The Medical Devices & Instruments industry median Quick Ratio is 1.87. Sera Prognostics' value of 2.12 is 13.7% above this industry median. Based on the distribution chart, Sera Prognostics ranks #380 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sera Prognostics has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' Quick Ratio compare to ECOR and OM?
According to the Medical Devices & Instruments industry distribution chart, Sera Prognostics ranks #380 out of 854 companies for Quick Ratio. This puts Sera Prognostics in the upper half of its industry. The industry median Quick Ratio is 1.87. Sera Prognostics' value of 2.12 is 13.7% above this benchmark. Historically, Sera Prognostics' own Quick Ratio has ranged from 1.22 to 34.53 over the past decade. While the company's 10-year median is 3.51 vs. the industry median of 1.87, Sera Prognostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.87, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sera Prognostics's current Quick Ratio of 2.12 is 13.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Sera Prognostics and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sera Prognostics's current Quick Ratio is 2.12, which is 40% below median its own 10-year median of 3.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Fairly Valued. The stock's GF Value™ is $1.86, compared to a current price of $1.83 — trading 1.9% below its estimated fair value. The current Quick Ratio is 2.12, which is 40% below median its 10-year median of 3.51 and 13.7% above the Medical Devices & Instruments industry median of 1.87. Sera Prognostics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Sera Prognostics (SERA), the current Quick Ratio is 2.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sera Prognostics (SERA) Overvalued in 2026?
Based on GuruFocus' analysis, Sera Prognostics stock appears to be undervalued.
The current stock price of $1.83 is trading 1.9% below its estimated GF Value™ of $1.86.
GuruFocus considers Sera Prognostics to be Fairly Valued.
Key valuation signals for SERA:
Quick Ratio: 2.12 (40% below median its 10-year median of 3.51)
GF Value™: $1.86 vs. price of $1.83 (1.9% below fair value)
Industry Position: 13.7% above the Medical Devices & Instruments median (#380 of 854)
No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
70GF Score
Get the complete analysis for SERA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SERA has been successfully added to your 
